RxDoctor Payments Data

Josee Cloutier, MD

Family Medicine · Groton, CTNPI 1790860419

Payments from drug & device makers

$1,033in general payments, 2019–2025

Across 70 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$451
  • AbbVie$301
  • Boehringer Ingelheim$142
  • AstraZeneca$41
  • Novartis$32
  • Avanir Pharmaceuticals, Inc.$26
  • plus $38 from 3 others

What the payments were for

  • Food & beverage$97695%
  • Education$575%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,033 in reported general payments places this provider in the 70th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$2,758
Medicare patients
13
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$41,854
Oxycodone Hcl22$747
Atorvastatin Calcium69$633
Levothyroxine Sodium64$570
Ibandronate Sodium19$407
Albuterol Sulfate HfaAlbuterol Sulfate14$402
Omeprazole23$363
Montelukast Sodium16$355
Lisinopril40$344
Metoprolol Tartrate28$328
Amlodipine Besylate40$319
Duloxetine Hcl11$235
Hydrochlorothiazide28$214
Eszopiclone11$214
Sertraline Hcl28$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$451$41,85419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Groton

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →